Arcus Biosciences prices $250M common stock offering

Arcus Biosciences (NYSE: RCUS) has priced an underwritten public offering of 14,285,715 shares of common stock at $17.50 per share, according to a company press release.

The biopharmaceutical company expects gross proceeds of $250 million before underwriting discounts, commissions, and offering expenses. All shares are being offered by Arcus Biosciences.

The company has also granted underwriters a 30-day option to purchase up to 2,142,857 additional shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on October 23, 2026, subject to customary closing conditions.

Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and Mizuho are acting as joint book-running managers for the offering.

A shelf registration statement related to the offering was filed with the U.S. Securities and Exchange Commission on February 25, 2026, and became effective upon filing.

You May Also Be Interested In

• Bolt Biotherapeutics acquires Prana Therapies, raises $120M
• Stem notified of NYSE noncompliance over market cap and equity
• Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results